• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to: Effects of dapagliflozin on liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled trial.

作者信息

Dalai Motij Kumar, Chandnani Sanjay Jagdish

机构信息

Department of Gastroenterology, Lokmanya Tilak Municipal Medical College and General Hospital, Sion, Mumbai, Maharashtra, India.

出版信息

Hepatol Int. 2025 Jun;19(3):698-699. doi: 10.1007/s12072-025-10803-9. Epub 2025 Mar 30.

DOI:10.1007/s12072-025-10803-9
PMID:40159418
Abstract
摘要

相似文献

1
Response to: Effects of dapagliflozin on liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled trial.回应：达格列净对非酒精性脂肪性肝病患者肝脏脂肪变性的影响：一项随机对照试验
Hepatol Int. 2025 Jun;19(3):698-699. doi: 10.1007/s12072-025-10803-9. Epub 2025 Mar 30.
2
Effects of dapagliflozin on liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled trial.达格列净对非酒精性脂肪性肝病患者肝脏脂肪变性的影响：一项随机对照试验。
Hepatol Int. 2025 Apr;19(2):405-414. doi: 10.1007/s12072-024-10758-3. Epub 2024 Dec 3.
3
Letter: Effects of dapagliflozin on liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled trial.信函：达格列净对非酒精性脂肪性肝病患者肝脏脂肪变性的影响：一项随机对照试验。
Hepatol Int. 2025 Jun;19(3):696-697. doi: 10.1007/s12072-025-10798-3. Epub 2025 Feb 26.
4
Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.评估钠-葡萄糖共转运蛋白 2 抑制剂达格列净对 2 型糖尿病合并非酒精性脂肪性肝病患者肝脂肪变性和纤维化的影响：应用瞬时弹性成像技术。
Diabetes Obes Metab. 2019 Feb;21(2):285-292. doi: 10.1111/dom.13520. Epub 2018 Oct 2.
5
Efficacy of dapagliflozin to treat nonalcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis.达格列净治疗2型糖尿病患者非酒精性脂肪性肝病的疗效：一项荟萃分析。
Medicine (Baltimore). 2025 Jan 3;104(1):e40836. doi: 10.1097/MD.0000000000040836.
6
Sodium glucose cotransporter-2-inhibitor dapagliflozin improves nonalcoholic fatty liver disease by ameliorating dipeptidyl-peptidase-4 protein expression in diabetic mice.钠葡萄糖协同转运蛋白2抑制剂达格列净通过改善糖尿病小鼠二肽基肽酶4蛋白表达来改善非酒精性脂肪性肝病。
Endokrynol Pol. 2023;74(2):190-196. doi: 10.5603/EP.a2023.0018. Epub 2023 Apr 11.
7
Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.达格列净对非酒精性脂肪性肝病患者的影响：一项随机对照试验的系统评价和荟萃分析。
Clin Res Hepatol Gastroenterol. 2022 Apr;46(4):101876. doi: 10.1016/j.clinre.2022.101876. Epub 2022 Mar 20.
8
Treatment of nonalcoholic fatty liver disease with dapagliflozin in non-diabetic patients.达格列净用于非糖尿病患者非酒精性脂肪性肝病的治疗。
Metabol Open. 2020 Feb 11;5:100028. doi: 10.1016/j.metop.2020.100028. eCollection 2020 Mar.
9
Dapagliflozin for nonalcoholic fatty liver disease: A systematic review and meta-analysis.达格列净治疗非酒精性脂肪性肝病：系统评价和荟萃分析。
Diabetes Res Clin Pract. 2022 Mar;185:109791. doi: 10.1016/j.diabres.2022.109791. Epub 2022 Feb 21.
10
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.达格列净和 n-3 羧酸对 2 型糖尿病患者非酒精性脂肪性肝病的影响：一项双盲随机安慰剂对照研究。
Diabetologia. 2018 Sep;61(9):1923-1934. doi: 10.1007/s00125-018-4675-2. Epub 2018 Jul 3.

本文引用的文献

1
Effects of dapagliflozin on liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled trial.达格列净对非酒精性脂肪性肝病患者肝脏脂肪变性的影响：一项随机对照试验。
Hepatol Int. 2025 Apr;19(2):405-414. doi: 10.1007/s12072-024-10758-3. Epub 2024 Dec 3.
2
Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials.5种钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂和4种胰高血糖素样肽-1（GLP-1）受体激动剂药物治疗非酒精性脂肪性肝病的疗效比较：一项基于GRADE评估的随机对照试验系统评价和网络荟萃分析。
Front Pharmacol. 2023 Mar 13;14:1102792. doi: 10.3389/fphar.2023.1102792. eCollection 2023.